Track Record

Management Teams and Boards of Life Science companies

e2v biosensors ltd is a wholly owned subsidiary of e2v technologies plc, an LSE listed company with an annual turnover of £174m, which designs, develops and manufactures components and subsystems in electronic tube, and sensor and semiconductor technologies for OEM companies. Employing around 1800 people worldwide, the Company has five European manufacturing sites, and a global network of sales and support offices.
e2v biosensors was established as a separate entity to commercialise a novel sensor technology for the quantification of proteins in fluids. The technology provides a highly flexible platform that has the potential to be applied across a wide range of sectors within the life sciences industry, a focus which is outside the company's core operations.
Ithaka is pleased to have led the review and validation of the market opportunity to commercialise the platform and is currently engaged in a further phase of work leading the development and execution of a commercial strategy to maximise value creation for e2v.
Paul Rodgers is leading this assignment and is currently interim CEO for e2v biosensors.

Ithaka has been providing management services to Theryte since February 2007 to assist the founder commercialise his technology.
Theryte is an oncology drug discovery company spin-out from the University of Liverpool. Ithaka’s Dr Bill Primrose is part-time CEO of Theryte and has led the development of a new business plan, negotiations of deals with key CRO’s and collaborations with other research organisations.
Dr Primrose has also obtained further financing for the business from new angel investors and existing investors, totalling £300,000 since the start of the appointment.

Ithaka worked with Dr Sabine Bahn of Cambridge University to found Psynova Neurotech in 2005 to exploit her research into biomarkers for neuropsychiatric disorders. Initially appointed by the Cambridge University Proof of Concept Fund to develop a business plan, Paul Rodgers was subsequently appointed as non-executive director to lead the commercial and fund raising activities.
Over £5M of funding has been secured from investors, a corporate partner and an EU Framework 7 grant;
A corporate deal with a US company in 2008 has positioned Psynova to launch its first product, a diagnostic test for schizophrenia, in 2009; and
A pharmaceutical company collaboration is exploring the use Psynova’s proprietary biomarkers in drug discovery and development.

deltaDOT is an exciting, early-stage Life Science company, commercialising novel detection technology originating from Imperial College, London. The company has developed a capillary electrophoresis platform with multiple applications for the separation and characterisation of biological molecules and particles.
Ithaka was engaged by deltaDOT to support development of a commercial strategy for the technology platform and is now commencing a second phase of work to provide additional marketing and product management resources as the Company’s customer base grows.
Working closely with the Company’s R&D, Sales and Operations Teams, Ithaka has assisted with prioritisation of the applications for commercialisation and is now helping to strengthen product and customer support packages in partnership with the deltaDOT team.

Expertise and experience